Metabolic & Cardiometabolic
metformin decreases insulin resistance
Part of: 💊 metformin
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Metformin lowers insulin / insulin resistance in PCOS (vs COCP comparator). Well-established insulin-sensitizer effect.
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Widen 1992 1992 · Diabetes | RCT | supports | moderate | clamp: metformin raised insulin-stimulated glucose disposal 25% |
| Trzcinski M et al 2026 · study_type: observational | observational | mixed | low | Prospective single-arm, PCOS women, metformin 500mg t.i.d. x3mo: fasting insulin decreased 19% (P=0.02); testosterone -13%, LPS -19% (all P<0.001) |
| Farkhondeh 2021 · Curr Oncol | meta-analysis | supports | moderate | MA: metformin reduced HOMA-IR in non-diabetic cancer patients |
| Murtaza S et al 2026 · study_type: meta-analysis | meta-analysis | supports | moderate | MA, 4 RCTs n=187 (non-diabetic on glucocorticoids): HOMA-IR MD -0.53 (95% CI -0.97 to -0.08, sig) vs placebo; but fasting insulin MD -2.26 (95% CI -5.90 to 1.38, NS) |
| Sun 2019 · Medicine (Baltimore) | meta-analysis | contradicts | moderate | MA: metformin showed no significant improvement in insulin resistance vs placebo in overweight/obese youth |
| Pan D et al 2026 · Research Square | meta-analysis | supports | moderate | MA/meta-regression, 14 RCTs n=882 (women with PMOS/PCOS-like syndrome): vitamin D improved HOMA-IR & fasting insulin; combo with metformin produced greater IR improvement than vitamin D alone |
| Davis 2018 · Clin Endocrinol (Oxf) | RCT | supports | moderate | Placebo-controlled RCT: metformin produced greater HOMA-IR reduction vs placebo in women on tamoxifen |
| Melin J, et al. 2024 · J Clin Endocrinol Metab | meta-analysis | supports | moderate | Pooled across 36 RCTs (GRADE): metformin lowered fasting insulin −27.12 pmol/L and triglycerides −0.15 mmol/L vs COCP; combination superior to COCP on insulin resistance (+0.44). |
| Dolati A et al 2026 · study_type: RCT | RCT | mixed | abstract only | RCT n=84, antipsychotic-induced weight gain: both empagliflozin & metformin(1000mg/d) improved glycemic/lipid params over 12wk; empagliflozin sig. greater HOMA-IR & fasting insulin reduction (p=0.012, p=0.005) than metformin |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.